Hosted on MSN

ImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s Positive

Shares of ImmunityBio, Inc. (IBRX) tumbled 18% on Monday afternoon after the company announced that it received a Refuse to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding ...
Morningstar

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary ...

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an ...
Morningstar

ImmunityBio Slides Following FDA Refusal-to-File Letter

Shares of ImmunityBio touched a 52-week low after the company received a refusal-to-file letter from the Food and Drug Administration for a supplemental biologics license application for ...